Business Wire

QUIT-LIKE-SWEDEN

10.4.2024 18:33:34 CEST | Business Wire | Press release

Share
Global Drive to ‘Quit Like Sweden’ Will Save Millions of Smokers’ Lives

INTERNATIONAL health experts today rallied behind a major new global effort to replicate Sweden’s success at eradicating smoking by embracing a comprehensive approach that could prevent many millions of premature deaths worldwide.

Quit Like Sweden (QLS), launched at a conference in Brasilia featuring medical professionals, politicians and policymakers, will motivate and support countries worldwide to emulate the triumph of Sweden, which is set to become the first nation to attain official ‘smoke-free’ status later this year.1

QLS founder Suely Castro, a Brazil-born harm reduction advocate, said: “Sweden has achieved this remarkable feat by ensuring that safer alternatives to smoking are accessible, acceptable and affordable.2

“A country where 49% of men used to smoke regularly has virtually wiped out this scourge by allowing its smokers to switch to products that pose just a fraction of the risks, such as snus [traditional smokeless tobacco] and other smoke-free alternatives like vapes and nicotine pouches.3

“Swedes are reaping the health dividend with significantly lower cancer cases and mortality rates compared to their European counterparts4. Now Quit Like Sweden will amplify this message globally, leveraging expertise and fostering collaboration across stakeholders to help countries replicate the Swedish Experience.”

Ms Castro was joined at the launch of her new platform by leading international harm reduction experts who unveiled new research showing that Brazil could save 1.36 million lives by 2060 by adopting the Swedish approach.5

Earlier research has shown that three million more Europeans would be alive today if other countries had implemented Sweden’s comprehensive approach to helping smokers quit.

Meanwhile, a study of low and middle-income countries (LMICs) shows that, through the adoption of Swedish-style policies, Kazakhstan could prevent 165 000 premature deaths in the next four decades, while South Africa, Bangladesh and Pakistan could save 320 000, 920 000, and 1 200 000 lives, respectively.6

Research co-author Dr Anders Milton, a former chair of the World Medical Association and former Secretary General of the Swedish Medical Association, said: “Sweden is winning the war against smoking with a comprehensive approach to tobacco control that supplements traditional cessation and preventive measures with an all-important added element: giving smokers the opportunity to switch to safer alternatives.

“It has set out a policy roadmap that should be treated as a gift to global public health and, potentially, one of the greatest ever breakthroughs in tackling non-communicable diseases (NCDs).

”That’s why QLS is so important. By spreading the message of the Swedish Experience to all corners, many millions of premature deaths - including almost 1.4 million here in Brazil - could be prevented in the next four decades.”

London-based Ms Castro said she had been motivated to launch QLS by her father, a lifelong smoker who lives in Bahia.

“Like Brazil’s other 22 million smokers, my father has been deprived of the lifelines given to the Swedes because of regulatory barriers and societal resistance towards alternative nicotine products.

“Quit Like Sweden aims to empower individuals - here in Brazil, and around the globe - to reclaim control over their health.”

-ENDS-

Notes to editors:

Quit Like Sweden is a platform for people who want to eradicate smoking. The smoking rate in Sweden, where once 49% of the male population smoked regularly, is about to fall below 5%, the level regarded by the World Health Organization as officially ‘smoke-free’. Quit Like Sweden aims to encourage other countries to replicate the Swedish Experience by using traditional cessation and prevention measures while making alternatives to smoking accessible, acceptable and affordable.

An official launch of Quit Like Sweden in Brasilia on April 10 features eminent guest speakers on a variety of topics:

Public policy: Swedish MP Jesper Skalberg Karlsson, Brazilian Senator Soraya Thronicke and Federico Fernandez, We Are Innovation.

Misinformation and the impact on consumers: Miguel Okumura, THR Brasil and Alexandro Lucian, DIRETA.

The Swedish Experience’s life-saving potential for Brazil: Dr Delon Human, Dr Anders Milton and Prof. Dr. Erika Magalhaes Suzigan.

Public health policymaking: Dr Roberto Sussman, Dr Konstantinos Farsalinos, Dr Christopher Russell, David Sweanor, Dr Marewa Glover, Jorge A. Costa e Silva.

1 https://smokefreesweden.org/wp-content/themes/smokefreesweden/assets/pdf/reports/Report%20The%20Swedish%20Experience%20EN.pdf
2 https://www.rcplondon.ac.uk/file/3563/download
3 https://www.ucl.ac.uk/news/2019/oct/e-cigarettes-may-help-over-50000-smokers-quit-england-each-year
4 https://www.researchgate.net/publication/345643346_Tobacco-related_mortality_SwedenEU_easier_readable_charts
5 per co-authored by Dr Delon Human, Dr Anders Milton & Dr Erica Suzigan, 2024.
6 https://smokefreesweden.org/lives-saved.pdf

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240410373868/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release

Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release

First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode

Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release

Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L

2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release

“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release

Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye